Azilsartan medoxomil API Manufacturers

Looking for Azilsartan medoxomil API 863031-21-4?

Description:

Here you will find a list of producers, manufacturers and distributors of Azilsartan medoxomil. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Azilsartan medoxomil 

Synonyms:

Azilsartan kamedoxomil , Azilsartan , Azilsartan medoxomilo , Azilsartanum medoxomilum , Edarbi  

Cas Number:

863031-21-4 

DrugBank number:

DB08822 

Unique Ingredient Identifier:

LL0G25K7I2

Azilsartan medoxomil is a type of Angiotensin Receptor Blockers

Angiotensin Receptor Blockers (ARBs) are a vital subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) commonly used in the treatment of hypertension and various cardiovascular conditions. ARBs work by selectively blocking the angiotensin II type 1 receptors, which are responsible for causing vasoconstriction and promoting the release of aldosterone, a hormone that regulates blood pressure and fluid balance.

These APIs are highly effective in reducing blood pressure by preventing angiotensin II from binding to its receptors, thereby dilating blood vessels and reducing peripheral resistance. By inhibiting the angiotensin II signaling pathway, ARBs help relax and widen the blood vessels, which subsequently lowers blood pressure.

Some commonly prescribed ARBs include losartan, valsartan, and candesartan. These drugs offer several advantages over other antihypertensive medications, such as a lower risk of side effects and better tolerability. ARBs are also considered beneficial for patients with certain comorbidities, including heart failure and diabetic nephropathy.

Pharmaceutical companies play a crucial role in the development and manufacturing of high-quality ARB APIs. Stringent quality control measures and adherence to regulatory guidelines ensure the safety, efficacy, and reliability of these APIs. Moreover, the market demand for ARBs is consistently growing, presenting a significant opportunity for pharmaceutical companies to cater to the increasing medical needs of patients suffering from hypertension and related cardiovascular conditions.

In conclusion, Angiotensin Receptor Blockers (ARBs) are a valuable subcategory of pharmaceutical APIs that effectively manage hypertension and cardiovascular diseases. With their ability to target the angiotensin II receptors, ARBs provide a reliable therapeutic option for patients and contribute to improving overall cardiovascular health.

Azilsartan medoxomil (Angiotensin Receptor Blockers), classified under Antihypertensive agents

Antihypertensive agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used to treat high blood pressure, also known as hypertension. These medications are designed to lower blood pressure and reduce the risk of associated cardiovascular complications.

Antihypertensive agents function by targeting various mechanisms involved in blood pressure regulation. Some common classes of antihypertensive agents include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCBs), and diuretics.

ACE inhibitors work by inhibiting the enzyme responsible for converting angiotensin I to angiotensin II, a hormone that constricts blood vessels. ARBs, on the other hand, block the receptors to which angiotensin II binds, thereby preventing its vasoconstrictive effects.

Beta-blockers reduce blood pressure by blocking the effects of adrenaline and noradrenaline, which are responsible for increasing heart rate and constricting blood vessels. CCBs inhibit calcium from entering the smooth muscles of blood vessels, resulting in relaxation and vasodilation. Diuretics promote the elimination of excess fluid and sodium from the body, reducing blood volume and thereby lowering blood pressure.

Antihypertensive agents are typically prescribed based on the individual patient's condition and specific needs. They can be used alone or in combination to achieve optimal blood pressure control. It is important to note that antihypertensive agents should be taken regularly as prescribed by a healthcare professional and may require periodic monitoring to ensure their effectiveness and manage any potential side effects.

In summary, antihypertensive agents play a vital role in the management of hypertension by targeting various mechanisms involved in blood pressure regulation. These medications offer significant benefits in reducing the risk of cardiovascular complications associated with high blood pressure.

• Sinoway industrial Co.,Ltd from China, product country of origin China
• AXXO GmbH from Germany, product country of origin World
• Shandong Octagon Chemicals Limited from China, product country of origin China
• Apino Pharma Co., Ltd. from China, product country of origin China
• SETV Global from India, product country of origin India
• Chongqing Land Tower from China, product country of origin China
• Acura Labs from India, product country of origin India
• Utopharm (Shanghai) Company Limited from China, product country of origin China
• Honour Lab from India, product country of origin India
• HEC Pharm from Germany, product country of origin Unknown
• Kolon Life Science from South Korea, product country of origin South Korea
• Zhejiang Hongyuan from China, product country of origin China
• ALP PHARM from China, product country of origin China
• Shaoxing Hantai Pharma from China, product country of origin China
• MSN Labs. from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.